Repositori Obert UdL
Publicación
Artículo científico (JournalArticle)
Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice, Impaired Oral Tolerance Induction in Diabetes Prone but not in Diabetes Resistant Mice Revealed by Cholera Toxin Subunit B-Peptide Fusion Proteins
The cholera toxin B subunit (CTB) has been used as adjuvant to improve oral vaccine
delivery in type 1 diabetes. The effect of CTB/peptide formulations on Ag-specific CD4+
T cells has remained largely unexplored. Here, using tetramer analysis, we investigated
how oral delivery of CTB fused to two CD4+ T-cell epitopes, the BDC-2.5 T-cell 2.5mi
mimotope and glutamic acid decarboxylase (GAD) 286–300, affected diabetogenic CD4+
T cells in nonobese diabetic (NOD) mice. When administered i.p., CTB-2.5mi activated
2.5mi+ T cells and following intragastric delivery generated Ag-specific Foxp3+ Treg and
Th2 cells. While 2.5mi+ and GAD-specific T cells were tolerized in diabetes-resistant
NODxB6.Foxp3EGFP F1 and nonobese resistant (NOR) mice, this did not occur in NOD mice.
This indicated that NOD mice had a recessive genetic resistance to induce oral tolerance to both CTB-fused epitopes. In contrast to NODxB6.Foxp3EGFP F1 mice, oral treatment in NOD mice lead to strong 2.5mi+ T-cell activation and the sequestration of these
cells to the effector-memory pool. Oral treatment of NOD mice with CTB-2.5mi failed to
prevent diabetes. These findings underline the importance of investigating the effect of
oral vaccine formulations on diabetogenic T cells as in selected cases they may have
counterproductive consequences in human patients., This work was supported by grants from the Spanish Ministry of Science and Innovation and European Regional Development Fund (FEDER; SAF2004- 02666, SAF2007-65291, SAF2010-18548, SAF2011-29319 to T.S.; SAF2007-31050E and SAF2008-02536 to C.M.), from the Spanish Ministry of Health and Consumption (PI040587 to T.S. and P041310 to C.M.), and from the European Community (MIRG-CT-2004-012692 to T.S.). T.S. was also supported by the Ramon y Cajal program from the Spanish Ministry of Science and ´ Innovation. D.S. is supported by NIH grants DK46266, DK97610, DK72473, as well as by grants from the Juvenile Diabetes Research Foundation and the American Diabetes Association.